Global contract research organization WuXi Biologics announced an important regulatory milestone today. The company successfully passed a Pre-License Inspection by the U.S. Food and Drug Administration. The federal agency inspected the MFG8 drug substance manufacturing facility located in Hebei. Crucially, this regulatory success directly supports biologics commercial manufacturing for a potential blockbuster autoimmune therapy.
During the seven-day process, three federal inspectors thoroughly reviewed the site. The quality management system was reviewed in relation to the manufacture of the core drug substance. The passage of this rigorous test confirms the company’s reputable track record of regulatory compliance. Moreover, it presents a quality system that is trusted worldwide. This testament is to the company’s manufacturing execution excellence.
Today MFG8 is a key node in the company’s worldwide network. The production site has twelve single-use bioreactors with a volume of 4,000L So the facility employs a sophisticated scale-out strategy. This approach allows for very flexible production capacities. These capacities scale easily from 4,000 L up to 20,000 L. The site also employs modern sustainable construction techniques. Beyond a rooftop photovoltaic system, the engineering teams rolled out advanced digital platforms. These particular technologies promote carbon reduction and improved waste recycling.
Dr. Chris Chen, CEO of WuXi Biologics, commented: “MFG8’s successful FDA Pre-License Inspection pass is a strong testament to WuXi Biologics’ commitment to global quality and compliance standards. This PLI pass reflects our sustained investment in a world-class quality system and our proven capability to support partners in advancing global commercial manufacturing. We are pleased to help bring this potential blockbuster autoimmune therapy to patients through our high-quality manufacturing capabilities. Moving forward, WuXi Biologics will continue to empower global partners with a reliable quality system and accelerate the delivery of innovative biologics to more patients worldwide.”
Securing Strict Global Quality and Compliance Standards
Historically, the firm maintains excellent compliance with strict industry benchmarks. By late 2025, the organization will have completed 46 regulatory inspections. This total includes 22 successful audits from the FDA and EMA. Consequently, the company secured 136 separate facility license approvals. The firm also holds a perfect 100% pass rate for FDA Pre-License Inspections.
Furthermore, the enterprise completed over 1,800 client audits. This number includes 230 inspections from European Qualified Persons. Today, the corporation runs 25 drug substance facilities. It also manages 18 distinct drug product facilities globally. These elite compliance capabilities foster long-term trust with international healthcare clients.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: PRNewswire.com
